Replies to post #115994 on Biotech Values

[DewDiligence]

Yes, I caught that brief segment on the webcast. As Wheeler said, MNTA is not running a safety-and-efficacy trial in support of its Copaxone ANDA, nor will it be required to do so as far as the company knows.